Core Framework & Diagram Rheumatoid Arthritis
7 月 28, 20261 Min Read Systemic Lupus Erythematosus
7 月 28, 2026It's not 'old-age joint pain' — rheumatoid arthritis is a sustained civil war targeting the joints
—— If you think morning stiffness lasting over an hour is 'just normal,' please keep reading.
I. Breaking the most common misconception: rheumatoid arthritis is NOT 'age-related degenerative joint disease'
|
RA Characteristic |
Details |
|
Nature |
Autoimmune disease (immune attack on synovium) |
|
Peak age |
30–55 years (can also onset in older age) |
|
Joint distribution |
Symmetric (both hands, both wrists, both knees simultaneously) |
|
Morning stiffness |
Over one hour |
|
Systemic symptoms |
Common (fatigue, low-grade fever, anemia) |
|
Inflammatory markers |
ESR, CRP, RF, anti-CCP elevated |
|
Treatment direction |
Immune suppression + targeted anti-inflammation |
Osteoarthritis (OA) is mechanical wear and degeneration of joint cartilage: predominant in those over fifty, asymmetric, mainly weight-bearing joints, morning stiffness usually under thirty minutes, no systemic symptoms, treatment direction is pain management + physical therapy + joint replacement. These two are fundamentally different diseases with completely different treatment directions. Treating RA as OA misses the most critical treatment window.
2. Why does the immune system attack joint synovium — the secret of protein citrullination
The core immunological puzzle of rheumatoid arthritis is: why does the immune system treat joint synovium as the enemy? The answer points to 'protein citrullination.' In smokers' lung tissue, periodontal infection gum tissue, and the inflammatory environment of joint synovium, PAD enzymes (peptidylarginine deiminases) are massively activated, converting arginine to citrulline in proteins, changing protein structure.
For people with specific HLA-DR4 genetic backgrounds, the immune system identifies 'citrullinated proteins' as 'foreign threats,' producing anti-citrullinated protein antibodies (ACPA — also the clinically measured 'anti-CCP antibody'). These antibodies can be detected in blood five to ten years before RA symptoms appear — meaning disease initiation begins far earlier than when joint pain is perceived. This is why managing pre-clinical RA is becoming an important research direction in rheumatology: if we could identify high-risk individuals before symptoms appear, could we implement preventive intervention before joint destruction begins?
3. Pannus — rheumatoid arthritis's most dangerous pathological structure
'Pannus' is an invasive tissue jointly formed by abnormally proliferating synovial fibroblasts, macrophages, T cells, and new blood vessels — like a 'tumor-like' covering that spreads from joint synovium margins toward cartilage and bone. Its destruction mechanisms are precise and multilayered: synovial fibroblasts continuously secrete matrix metalloproteinases (MMP) that directly digest cartilage matrix; TNF-α and IL-1β activate osteoclasts, causing peri-articular bone erosion; IL-6 causes systemic effects including anemia (suppresses iron metabolism), fatigue (central effects), and elevated CRP (hepatic acute phase response).
These three cytokines — TNF-α, IL-1β, IL-6 — became the main attack targets of modern RA targeted therapy. Biologics that emerged after 2000 (etanercept, infliximab, tocilizumab) precisely cut inflammatory signals by blocking these cytokines or their receptors. These drugs transformed RA's treatment landscape: before biologics, late-stage joint deformity was almost inevitable. After widespread biologic use, the proportion of patients achieving sustained remission significantly increased and the need for joint replacement surgery dropped markedly.
4. Beyond joints — rheumatoid arthritis is a systemic disease
Rheumatoid arthritis isn't only a joint disease; persistent systemic inflammation can affect multiple organs. Cardiovascular involvement is the most serious extra-articular manifestation: RA patients' cardiovascular disease risk is one and a half to two times that of the general population; persistent systemic inflammation accelerates atherosclerosis, and this risk exists independently of traditional cardiovascular risk factors (hypertension, diabetes, smoking).
Pulmonary involvement affects approximately ten to twenty percent of RA patients: interstitial lung disease (ILD) is one of the leading causes of RA mortality; pleuritis and pulmonary nodules are also common. Ocular involvement (scleritis, sicca syndrome secondary to Sjögren's) requires regular ophthalmology checks. Osteoporosis arises both from long-term inflammation's effects on bone metabolism and from corticosteroids commonly used in treatment — bone density management is content that can't be overlooked throughout RA follow-up.
5. Today's rheumatoid arthritis is no longer 'incurable'
'Treat-to-Target' (T2T) strategy is the core concept of modern RA management: using 'clinical remission' or 'low disease activity' as explicit treatment goals, evaluating disease activity with standardized scales (like DAS28) every one to three months, and promptly adjusting plans when targets aren't met. This strategy reduced RA patients' long-term joint damage rates by over fifty percent — one of the most important drivers of RA treatment progress.
The current treatment ladder is clear: conventional synthetic DMARDs (methotrexate as first-line, usually combined with folic acid and hydroxychloroquine) for initial treatment; if treatment goals aren't met within three months, upgrade to biologic DMARDs (TNF inhibitors, IL-6 receptor inhibitors, B cell depletion agents); JAK inhibitors (tofacitinib, baricitinib — small-molecule oral targeted drugs) are an alternative to biologics. Over forty percent of RA patients achieve 'clinical remission' under standardized treatment — joints not swollen or painful, inflammatory markers normal.
6. What patients can do beyond standardized treatment
Standardized drug treatment is the foundation of RA management, but lifestyle cooperation is equally important. Regular low-to-moderate intensity exercise (swimming, walking, yoga, water aerobics) doesn't worsen joint damage — it improves joint function, reduces fatigue, and lowers cardiovascular risk. Many RA patients avoid all exercise because of pain, but this actually causes muscle atrophy and declining joint stability.
The importance of quitting smoking in RA patients can't be overstated: smoking is not only an RA risk factor, but after diagnosis also reduces biologic drug efficacy, accelerates joint destruction, and increases cardiopulmonary complication risk. Treating periodontal disease has unique significance in RA patients: P. gingivalis is a known citrullinated protein trigger; controlling periodontal disease may help reduce persistent autoimmune stimulation.
Frequently Asked Questions